Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aperture Bio
Aperture Bio

Aperture Bio

Pre-Seed

Aperture Bio: Rapid, ultra-sensitive lab diagnostics to quantify drug efficacy and failure.

HQ
Allston-Brighton, MA, US
Founded
2022
Accelerator
Techstars logoTechstars: Boston2023
Overview
Compare
Fundraising
Employees

Aperture Bio, founded with the mission to revolutionize laboratory diagnostics, focuses on providing rapid and ultra-sensitive solutions to quantify drug efficacy and failure. The company's core vision is to accelerate precision medicine by unlocking the role of the single-cell proteome in drug response. Aperture Bio offers cutting-edge diagnostic services that enable healthcare providers and researchers to understand how, why, and when drugs fail, thereby improving treatment outcomes and advancing personalized medicine.

Notable affiliations include participation in the Techstars Boston 2023 class, which underscores the company's innovative approach and potential for growth. Key achievements include the development of their proprietary technology that significantly enhances the sensitivity and speed of drug response diagnostics. Aperture Bio's impact lies in its ability to provide critical insights into drug performance, ultimately contributing to more effective and personalized healthcare solutions.

Aperture Bio - Similar Companies

Spear Bio logo

Spear Bio

spear.bio

BioAmp diagnostics logo

BioAmp diagnostics

bioampdx.com

Signatur Biosciences logo

Signatur Biosciences

signatur.bio

BioAnalytics logo

BioAnalytics

Pattern Bioscience logo

Pattern Bioscience

pattern.bio

Probius logo

Probius

probius.bio

Nanopath logo

Nanopath

nanopathdx.com

OmniVis logo

OmniVis

Prompt Diagnostics logo

Prompt Diagnostics

prompt-dx.com

Apic Bio logo

Apic Bio

Accelevir Diagnostics logo

Accelevir Diagnostics

Curie.Bio logo

Curie.Bio

curie.bio

Akili Labs logo

Akili Labs

Amplified Sciences logo

Amplified Sciences

Mission Bio logo

Mission Bio

Aperture Bio - Quick Facts

Who are Aperture Bio's competitors?

Companies similar to Aperture Bio include Spear Bio, BioAmp diagnostics, Signatur Biosciences and BioAnalytics.

When was Aperture Bio founded?

Aperture Bio was founded in 2022.

Where is Aperture Bio's headquarters located?

Aperture Bio's headquarters is located in Allston-Brighton, MA, US.

When was Aperture Bio's last funding round?

Aperture Bio's most recent funding round was for $120k (USD) in August 2023.

How much has Aperture Bio raised to-date?

As of Aug 22, 2023, Aperture Bio has raised a total of $120k (USD).

How many employees does Aperture Bio have?

Aperture Bio has 30 employees as of Feb 5, 2024.

Aperture Bio - Classification

Industry
  • Professional Service Companies
Ownership
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Lab Diagnostics
Tags
  • Biotech
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 9 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified